Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 10/20 | 0.48 |
| ▸ | CTSS | P25774 | 7/20 | 0.48 |
| ▸ | CTSB | P07858 | 6/20 | 0.48 |
| ▸ | CTSK | P43235 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4402028 | 0.95 | CTSL (0.44) | CTSLCTSSCTSBCTSKMEN1 | |
| SCHEMBL10131069 | 0.89 | HDAC3 (0.48) | CTSLCTSSCTSBCTSKMEN1 | |
| SCHEMBL10131045 | 0.89 | CTSL (0.45) | CTSLCTSSCTSBCTSK | |
| SCHEMBL4402043 | 0.89 | CYP1A2 (0.51) | CTSLCTSSCTSBCTSKMEN1 | |
| SCHEMBL10073683 | 0.86 | CTSL (0.49) | CTSLCTSSCTSBCTSKMEN1 | |
| SCHEMBL15764484 | 0.85 | CTSL (0.49) | CTSLCTSSCTSBCTSK | |
| SCHEMBL30843763 | 0.80 | GAA (0.53) | CTSLALDH1A1KMT2A | |
| SCHEMBL12019155 | 0.80 | CTSL (0.44) | CTSLCTSSCTSBCTSKMEN1 | |
| SCHEMBL12020041 | 0.79 | CTSL (0.43) | CTSLCTSSCTSBCTSKMEN1 | |
| SCHEMBL7793390 | 0.77 | KMT2A (0.57) | CTSLCTSSCTSKALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150175559-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | MARQUETTE UNIVERSITY (US) | 2015-06-25 | — | — | US | disclosed |
| US-8962692-B2 | Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings | MARQUETTE UNIVERSITY (US) | 2015-02-24 | — | — | US | disclosed |
| US-8173809-B2 | Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings | MARQUETTE UNIVERSITY (US) | 2012-05-08 | — | — | US | disclosed |
| US-20090281109-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | MARQUETTE UNIVERSITY | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281109-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | CTH, SLC7A11, CBS | CTSL 544/4885CTSS 130/4885CTSB 404/4885 |
| US-20150175559-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | SLC7A11, CBS, CTH | CTSL 671/4885CTSS 241/4885CTSB 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.